Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
Silo Pharma announced that the European Patent Office has indicated its intent to grant a patent covering preventative use of serotonin 4 (5-HT4) receptor agonists to prevent stress-induced fear and depressive-like behaviors. This patent strengthens Silo Pharma's intellectual property portfolio in major European markets and supports its strategic a…